"Zepbound: A Promising Solution for Sleep Apnea and Obesity"

Eli Lilly's new weight loss drug tirzepatide, already approved for obesity, has shown promising results in reducing episodes of obstructive sleep apnea in people with obesity. In addition to significant weight loss, participants experienced easier breathing at night and fewer sleep apnea episodes. Tirzepatide belongs to a class of drugs known as incretins, which mimic gut and brain hormones important for regulating hunger and metabolism. The drug's potential to address both obesity and sleep apnea simultaneously could lead to a new treatment option for the underlying disease of sleep apnea.